# Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects

> **NCT02806219** · PHASE1 · COMPLETED · sponsor: **UCB BIOSCIENCES, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DEVICE:** Prefilled syringe (PFS)
- **DEVICE:** e-Device

## Key facts

- **NCT ID:** NCT02806219
- **Lead sponsor:** UCB BIOSCIENCES, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806219, "Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02806219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*